Expression Profile and Role of the IGF2BP1-3 Genes During Human in vitro Osteogenic Differentiation
Robinson L., Cole H., X Melton E., Yin X., Omandan N., Cubbage N.
Prospective Study, published in Cell Biochem Biophys (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Cell Biochem Biophys (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41801615
- PMCID
- PMC13233644
- DOI
- 10.1007/s12013-026-02033-z
Abstract (original English)
MicroRNAs (miRNAs), including the let-7 family, have been shown to regulate osteogenic differentiation of human mesenchymal stem cells. Moreover, let-7 miRNAs were upregulated in the muscle tissue of patients who formed ectopic bone compared to patients who did not form ectopic bone after injury. Here we investigated the expression and role of the insulin-like growth factor 2 binding protein genes (IGF2BP1, IGF2BP2, and IGF2BP3), known targets of the let-7 miRNAs, during human in vitro osteogenic differentiation. Let-7a and let-7b were slightly upregulated on osteogenic differentiation day 7, downregulated on day 14, and slightly upregulated or unchanged on days 21 and 28. Let-7d and let-7f were upregulated on days 7, 14, 21, and 28. IGF2BP1 and IGF2BP2 were mildly modulated or unchanged on days 7, 21, and 28, and significantly downregulated on day 14, whereas IGF2BP3 was slightly upregulated on day 7 and slightly downregulated on days 14, 21, and 28. Following IGF2BP1 knockdown (KD), ALPL was upregulated on days 7 and 14, while RUNX2 and BGLAP were mildly upregulated on day 7 and mildly downregulated on day 14. We also observed more calcium deposits on IGF2BP1-KD compared to the control on osteogenic day 14. Finally, downregulation of the IGF2BP2-3 genes had no major effects on osteogenic differentiation. Altogether, we characterized the differential expression of members from
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.